Improving clozapine utilization will require continued advocacy, drug sponsor interest, and FDA support to address REMS issues
Expert Review of Clinical Pharmacology · 2023
DOI: 10.1080/17512433.2023.2183192 ↗Kurz gefasst
Editorial in der Zeitschrift Expert Review of Clinical Pharmacology, 2023. Verfasst von Jonathan G Leung und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic, Rochester. Hauptthemen laut MEDLINE: Clozapine. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Significant research and clinical efforts have improved the safety of clozapine since FDA approval. This includes work resulting in strategies to prevent, detect, and manage clozapine-related adverse drug reactions (ADRs) such as gastrointestinal hypomotility and inflammatory reactions [1–4]. Tools and guidelines to screen for clozapine-related ADRs and awareness of how clozapine clinics help support the use of clozapine have also advanced care [5–7]. Continued efforts to improve clozapine prescribing are critical as clozapine is the only FDA approved medication indicated for treatment-resistant schizophrenia and reduction of suicidality in schizophrenia or schizoaffective disorder. Unfortunately, literature suggests clozapine use remains suboptimal in the US and throughout parts of the world [8,9]. In the US, the Clozapine Risk Evaluation and Mitigation Strategy (REMS), implemented to ensure completion of hematologic monitoring, remains a major barrier to clozapine use. Prior to the turbulent rollout of the 2021 REMS, the REMS website displayed the trademarked phrase, ‘No blood, no drug,’ which may still be engrained in the minds of healthcare professionals, caretakers, and patients. Not only is this phrase not true, as exceptions existed, it could be interpreted that hematologic risks remain constant throughout the duration of clozapine exposure. This is also not true [10]. Unfortunately, the ‘No blood, no drug’ slogan continues to have real-world negative impacts through the refusal to dispense clozapine from community pharmacists unaware of REMS flexibilities. This was highlighted by situations encountered during the COVID-19 pandemic (e.g. patient in quarantine without access to a laboratory) and the 2021 REMS rollout (e.g. inaccessible call center, preventing enrollment). During these times, some pharmacies denied clozapine prescriptions despite clear guidance from the FDA and international expert consensus to allow and justify monitoring variance in certain patients (e.g. every 3-month monitoring for patients on clozapine at least 1 year without prior hematologic abnormalities) [11]. Yet, given perceived liabilities, prescribers in many countries likely grappled with how to adopt variance from the usual hematologic monitoring requirements. With some REMS parameters still suspended by the FDA, now may be a time for major reformation. 2. How did we get here?
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Mayo Clinic, Rochester.
- Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD, USA.
- Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.
ORCID-Profile: Jonathan G Leung
Zitieren
APA
Leung, J. G., Ehret, M., Love, R. C., & Cotes, R. O. (2023). Improving clozapine utilization will require continued advocacy, drug sponsor interest, and FDA support to address REMS issues. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2023.2183192
Vancouver
Leung JG, Ehret M, Love RC, Cotes RO. Improving clozapine utilization will require continued advocacy, drug sponsor interest, and FDA support to address REMS issues. Expert Review of Clinical Pharmacology. 2023. doi:10.1080/17512433.2023.2183192
BibTeX
@article{Leung2023,
author = {Leung, Jonathan G and Ehret, Megan and Love, Raymond C and Cotes, Robert O},
title = {Improving clozapine utilization will require continued advocacy, drug sponsor interest, and FDA support to address REMS issues},
journal = {Expert Review of Clinical Pharmacology},
year = {2023},
doi = {10.1080/17512433.2023.2183192}
}
EUVIMED